APRE — Aprea Therapeutics Share News
0.000.00%
Last trade - 00:00- $6.52m
- -$33.99m
- $0.29m
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall
Brief: Aprea Therapeutics Highlights Positive Emerging Clinical Activity For Wee1 Inhibitor, Apr-1051
Aprea Therapeutics Q4 net loss narrows as R&D costs fall
Brief: Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051
Brief: Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics
NASDAQ RESUMED AT 01:41 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:36 PM
NASDAQ RESUMED AT 01:32 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:27 PM
NASDAQ RESUMED AT 01:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:19 PM
NASDAQ RESUMED AT 11:57 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:52 AM
Brief: Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026
Aprea Therapeutics' Q3 net loss narrows